Case report: A durable response to Anastrozole re-challenge with Everolimus in a patient with advanced-stage estrogen receptor-positive breast cancer

Authors

• Vincent Emma P Weiss, Commonwealth University St-Lucia, Saint Lucia.Follow

Article Type

Case Report

Abstract

Estrogen receptor-positive breast cancer is a heterogeneous disease characterized by its dependence on estrogen for growth and progression. Although hormonal therapy remains the cornerstone of treatment, many patients eventually develop resistance, leading to recurrence and disease progression. This case report describes a durable response to a rechallenge with Anastrozole (Arimidex) in combination with Everolimus (Afinitor), an mTOR inhibitor, in a patient with advanced (stage IV) ER+ metastatic breast cancer.

Keywords

stage IV ER+ breast cancer, mTOR inhibitor, treatment rechallenge

Recommended Citation

Weiss, Vincent Emma P (2025) "Case report: A durable response to Anastrozole re-challenge with Everolimus in a patient with advanced-stage estrogen receptor-positive breast cancer," Iraqi National Journal of Medicine: Vol. 7 : Iss. 1 , Article 21.
Available at: https://doi.org/10.37319/iqnjm.7.1.22

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License